Other therapeutic strategies have been tested, but due to the genetic variability and the clonal evolution of CCA, clinical studies with targeted therapies (e.g., monoclonal antibodies and tyrosine kinase inhibitors against EGFR, VEGF, FGFR2) have shown minimal success in terms of overall survival (OS) [14]. This evidence concerns the gene EGFR and cholangiocarcinoma.